Split History
ETFs Holding RGLS »    RGLS Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat diseases. Co.'s key product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. Co. has multiple programs in various stages of preclinical development including RGLS5579 as a clinical candidate in its glioblastoma multiforme program, its preclinical programs targeting the Hepatitis B virus and Non-Alcoholic Steatohepatitis program. According to our RGLS split history records, Regulus Therapeutics has had 1 split.
RGLS split history picture
Regulus Therapeutics (RGLS) has 1 split in our RGLS split history database. The split for RGLS took place on October 04, 2018. This was a 1 for 12 reverse split, meaning for each 12 shares of RGLS owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 83.3333333333333 share position following the split.

When a company such as Regulus Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the RGLS split history from start to finish, an original position size of 1000 shares would have turned into 83.3333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Regulus Therapeutics shares, starting with a $10,000 purchase of RGLS, presented on a split-history-adjusted basis factoring in the complete RGLS split history. RGLS split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 10/09/2012
End date: 06/23/2021
Start price/share: $52.56
End price/share: $0.98
Dividends collected/share: $0.00
Total return: -98.14%
Average Annual Total Return: -36.70%
Starting investment: $10,000.00
Ending investment: $186.34
Years: 8.71
Date Ratio
10/04/20181 for 12
RGLS is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

RHE Split History
RMD Split History
RNN Split History
RNVA Split History
ROCM Split History
ROKA Split History
ROSG Split History
RPTP Split History
RSLS Split History
RTTR Split History

Also explore: RGLS shares outstanding history

Trisura Group Ltd. (TSU.CA)
BetaPro NASDAQ-100 2x Daily Bull ETF (HQU)
BetaPro S&P 500 2x Daily Bull ETF (HSU)
BetaPro S&P/TSX Capped Energy 2x Daily Bull ETF (HEU)
BetaPro S&P/TSX Capped Financials 2x Daily Bull ETF (HFU)
BetaPro S&P/TSX 60 2x Daily Bull ETF (HXU)
BetaPro Crude Oil Leveraged Daily Bull ETF (HOU)
Horizons Big Data & Hardware Index ETF (HBGD.U)
Horizons Big Data & Hardware Index ETF (HBGD)
Horizons NASDAQ-100 Index ETF (HXQ.U)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

RGLS Insider Buying

RGLS Split History | www.SplitHistory.com | Copyright © 2013 - 2021, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.